Podcasts about millenium

This should be a given for Berserk, but these chapters get dark, tragic, and disturbing. Sadly, it's our beautiful, but flawed boy, Berk, himself, who is the perpetrator of this messed up stuff. But it's not that simple! Much to discuss here as the Beast of Darkness begins to take its hold on old Gutsy, causing him to wrestle with (and largely lose against) his deepest desires…resulting in the simple minded, traumatized Casca to recoil from him as a villain for the foreseeable future. Follow No Guts, No Glory on Instagram: https://www.instagram.com/nogutsnoglorypc/ Check out Joey and Ryan's Renaissance Martial Arts organization: https://www.thearma.org/ Check out Steve and Joey's other podcast: https://podcasts.apple.com/us/podcast/probing-ancient-aliens/id1321801647 https://open.spotify.com/show/3aREEXpe4DE37LsNkUxntW Check out Steve and Joey's Patreon for that other podcast: https://www.patreon.com/probingancientaliens

Suite mais pas encore fin de notre périple au sein de la contrastée période Millenium avec Godzilla X Mechagodzilla (2002) & Godzilla, Mothra, Mechagodzilla: Tokyo S.O.S. (2003)Ce diptyque, appelé parfois "saga Kiryu" met en scène - ça va vous surprendre - Mechagodzilla dans sa lutte pour protéger l'humanité de la menace Godzilla.Deux films qui se suivent - plus ou moins, on va y revenir - et qui sentent les vieilles recettes après le chaos et la fureur de GMK.Egalement au programme : Mothra, des soupçons de male gaze à l'encontre du réal, et une influence à peine perceptible de Evangelion.Attention, cet épisode parle largement de mechas qui aiment montrer leur mite !Très bonne écoute.

This message was given by the late Rev. Howard E. Tucker, pastor of the former Calvary Presbyterian Church in Wilkinsburg, PA.  He was a graduate of Wheaton College and Dallas Theological Seminary.  The sermons were first broadcast on Pittsburgh's radio station, KDKA, during the fifties, sixties, and seventies.They can now be heard every Sunday evening on Pittsburgh's radio station WORD FM 101.5 or WORDFM.com at 9:45 PM, or 24/7 by typing in "Timeless Treasures from God's Word" in the search bar of your computer or smart phone.  Pastor Tucker's son, Timothy, now voices the messages.

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

In this surprisingly beefy episode, we cover three chapters that are short on pages but overflowing with meaty meat goo inside for you to sip on for almost three hours. Griffith's war demons begin to make their pilgrimage to him, including first appearances of the fire-breathing Grunbeld and the mysterious Rakshas. The real meat of tonight's meat goo treat is the origin stories of Serpico (more like Slurp-ico. YUM.) and Farnesse's (I wish she was Close-nesse. YUM.) origin story: a tale of parental abandonment and trauma, chaotic eroticism, possible incest, and animal torture. Enjoy! Follow No Guts, No Glory on Instagram: https://www.instagram.com/nogutsnoglorypc/ Check out Joey and Ryan's Renaissance Martial Arts organization: https://www.thearma.org/ Check out Steve and Joey's other podcast: https://podcasts.apple.com/us/podcast/probing-ancient-aliens/id1321801647 https://open.spotify.com/show/3aREEXpe4DE37LsNkUxntW Check out Steve and Joey's Patreon for that other podcast: https://www.patreon.com/probingancientaliens

Two lecturers from the Technological University of the Shannon (TUS) have been highly commended for their exceptional contributions to teaching at the prestigious Regional Teaching Excellence Awards. The awards, which took place at the Millenium theatre on the grounds of the TUS Moylish campus in Limerick last week, celebrated seven finalists from across the region, representing TUS, Mary Immaculate College (MIC) and University of Limerick (UL). Among the seven shortlisted candidates which included the winner, three lecturers received high commendations - two of them hailing from TUS's Limerick School of Art and Design (LSAD): Damien O'Connell, Programme Coordinator for Critical and Contextual Studies, and Clare-based Gianna Tomasso, Programme Leader for the MA in Instructional and Learning Design. To discuss this further, Alan Morrissey was joined by Programme Leader for the MA in Instructional and Learning Design and is an Assistant Lecturer at Limerick School of Art and Design, Gianna Tomass. Photo(C): Clare FM

In episode 214, host Galit Friedlander and guest Kwasi Ohene-Adu (dancer, technologist, and founder/CEO of Groovetime) get into a conversation that's part dance history, part tech-forward vision, and fully rooted in the reality of what dancers are navigating today. From street performing and coding his own programs in college to building a platform that connects dance trends, AI, and digital ownership, Kwasi shares what he's learned and where he believes the industry is headed. This episode covers everything from soft power and viral culture to how dancers can create new revenue paths without waiting on the old system to catch up. Expect stories, sharp insights, and future-focused ideas—plus a few unexpected laughs along the way. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ On-Demand Workout Programs -https://galit-s-school-0397.thinkific.com/collections Learn more about investing in Groovetime by visiting https://www.startengine.com/offering/groovetime. Check out Groovetime on Instagram and TikTok. Listen to DanceSpeak on Apple Podcasts and Spotify.

In episode 213, host Galit Friedlander and guest, Gerran Reese (Beyoncé, Kaytranda, Dancing With the Stars, Nike, Monsters of Hip-Hop), deconstruct the topic of virality in the dance world, Gerran's journey from a young working dancer in PDX to becoming a sought-after teacher in LA/globally, and the deeper work of staying true to yourself in an industry that doesn't always make it easy. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ On-Demand Workout Programs -https://galit-s-school-0397.thinkific.com/collections You can connect with Gerran Reese on Instagram. Listen to DanceSpeak on Apple Podcasts and Spotify.

Send us a text198 Bonus Episode (Thoughts): ButterflyMy class had a science project at my school. They followed the larva until it became a butterfly. And I realized that when my marrige came to a dead halt, I retracted into the cocoon. But it was also there I remade myself to a Butterfly. That is what this episode is about.  Next episode will be 2025-06-06 and it will include a meditation! If you like this podcast please share it with a friend! Share the Light. Spread the Light. Shine!LDS AND MEDIUM PODCAST BACKGROUND:I was born into the Church of Jesus Christ of Latter-Day Saints, or LDS for short. All my life I felt awkward and out of place, not because of my religion, but because of my spiritual gifts. It was hard to combine the idea of what first seemed like two separate worlds. So my whole life I have tried. I have learnt more about my gifts, and stayed faithful to my faith. But then I heard people left the church because it seems impossible to combine the two. So I am here, to try and mend the rift. To show that it is possible to be both LDS and to have, and use, our spiritual gifts. I am not alone on this journey, but my sister, who just is waking up to her spiritual gifts is by my side and she will also share her story.Jesus Christ, our older brother, was a healer. He asked us to love one another. So let´s follow in his footsteps. Please join me on this journey, let´s make a community of strong spiritual LDS, or whatever religion you belong to, and all work together to make this world a better place.If you like what I do, then you can find me here:https://linktr.ee/ldsandmediumIf you have words of support or stories that you anonymously want me to share please write me at ldsandmedium@gmail.com. I will try and answer all your emails BUT I am very busy with my life and I hope you can have some patience with me.If you would like access to the Podcast before it is released, all the bonuses and extra trainings and the meditation prayers as an mp3 you can support me on Patreon: https://www.patreon.com/ldsandmedium or send a Donation through Paypal. It will also be available as an archive that you can subscribe to on https://payhip.com/LDSandMediumDISCLAIMER: This Podcast is not official LDS doctrine, nor is it in any way financially supported by the LDS church. All the content is either our own personal thoughts and reflections or stories from our lives or the lives of others. Any quotes included will come from the Bible, The Book of Mormon or other scriptures, Church publications, hymns, General Conference or spiritual sites. This podcast is also for entertainment purposes only and you are always the one responsible for actions you decide in your own life, as we are all responsible always only for ourselves. Support the show

Aujourd'hui on parle d'un des pics de la...carrière de Godzilla, avec Godzilla, Mothra and King Ghidorah: Giant Monsters All-Out Attack, dit GMK, la perle noire que Shusuke Kaneko a su dissimuler au sein de la tristoune période Millenium.Un épisode plein de rédemptions : de Jacques Chirac à King Ghidorah.Très bonne écoute !

Ziinling Ciang Theih Huai Thu Te // Health talk.Kawikawi + Nang Kong Zuan Hi // Chin Gospel Songs.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

E ftuar në “Live From Tirana” me Ronaldo Sharkën, ka qenë Zhaklin Lekatari, për të folur më shumë mbi Gjeneratën Z, si dhe dashurinë sipas tyre. Nga ndryshon Gjenerata Z nga ajo Millenium?

Griffith...is...back. But Griffith don't GOT back, because we know he still retains his little flat buns despite his divine reincarnation into non-astral flesh. Zodd is his big ridin' pony, he saves Casca (surprising even unto himself), and starts amassing a crew against a major Kushan attack against Midland. Ah yes: Puck determines Guts' and crew's ultimate destination for about the next fifteen years of publishing.

Asif Kapadia to brytyjski reżyser znany z dokumentalnego stylu łączącego archiwalne materiały z narracją bez tradycyjnych wywiadów. Zdobył międzynarodowe uznanie dzięki filmowi Senna (2010), opowiadającemu o brazylijskim kierowcy Formuły 1 Ayrtonie Sennie. Jego kolejny film, Amy (2015), o życiu Amy Winehouse, zdobył Oscara za najlepszy pełnometrażowy film dokumentalny. Kapadia wyreżyserował także Diego (2019), ukazujący burzliwe życie piłkarza Diego Maradony.

Ask Paul Tripp is a weekly podcast resource from Paul Tripp Ministries. Each week, pastor and best-selling author Dr. Paul David Tripp answers your questions about anything and everything, connecting the transforming power of Jesus Christ to everyday life in the process. Today's question comes from a listener preparing to lead a Bible study on the Book of Revelation. She's wondering if Paul holds to a particular view of Revelation, like Idealism, Preterism, Historicism, or Futurism? And why are there so many different approaches to understanding this book in the first place?If you have a question you'd like to ask Paul, you can email ask@paultripp.com or submit it online at PaulTripp.com/Ask.Paul Tripp's 5-Minute Bible Studyhttps://www.paultripp.com/biblestudy

Will England just pivoted his $10B AUM hedge fund to go all in on AI with a firm-wide email:“I wrote this email using ChatGPT—you should too. As a hedge fund, we should be ashamed to leave money on the table by ignoring AI.”It's working: 75% of his 400-person team are using ChatGPT daily—and Walleye is well on its way to transforming into an AI-first juggernaut. They record every meeting, use LLMs to ingest and analyze earnings reports, and are building “The Borg”—a firmwide intelligence layer.What's surprising? Will isn't some AI hype man: He's the CEO, CIO, and managing partner of Walleye Capital, a multi-strategy hedge fund competing with firms like Citadel, Millenium, and Point72. He's Princeton and Oxford educated, but he's based in Minnesota, doesn't have an X account, and rarely gives interviews.In my experience, teams go as their CEO goes—and Will is the best example of a CEO going all in on AI that I've seen. "It would be irresponsible not to go after AI with maximum discipline and intensity," Will told me—and in this episode he lays out his exact playbook for doing it.We get into:Why AI is essential operating leverage. At Walleye, using AI is treated like using email or Excel. Ignoring it means getting left behind—in an industry where information = money, every edge counts. England makes this not optional for anyone, backed by internal leaderboards and cash incentives.How Will uses AI for journaling and decision-making. Will journals every day using ChatGPT, which helps him with everything from decision-making at work to reflecting on his family life to tracking his workouts. How Will pivoted his billion dollar firm. Will's commitment to AI isn't theoretical—he announced AI as the new standard for work at Walleye, and made avoiding it unacceptable. How to lead during times of technological change. Will leads with an ethic of personal responsibility: "If we get disrupted by AI, that's on me.”Why students of history do better at handling the future. Will sees today like the 1860s–1910s era—when the Industrial Revolution introduced factories and railroads and the skills and roles needed inside of companies transformed quickly.How Will uses AI to write faster. Will uses ChatGPT to help him draft emails or memos that would have taken hours in 15 minutes. He bullets out of his thoughts and then uses LLMs to turn that into polished prose. Having AI handle the linguistic syntax gives him more time for conceptual thinking.This is a must-watch for anyone who wants to lead a team through change with clarity and conviction.  Sponsor:Attio: Go to⁠⁠⁠ https://www.⁠⁠⁠⁠attio.com/every⁠⁠⁠⁠ and get 15% off your first year on your AI-powered CRM.Want even more?Sign up for Every to unlock our ultimate guide to prompting ChatGPT here: https://every.ck.page/ultimate-guide-to-prompting-chatgpt. It's usually only for paying subscribers, but you can get it here for free.To hear more from Dan Shipper:Subscribe to Every: https://every.to/subscribe Follow him on X: https://twitter.com/danshipper Timestamps:Introduction: 00:00:51What pushed Will to go all in on AI: 00:03:25Inside the ‘AI-first' memo Will shared at Walleye: 00:14:08Why you shouldn't be afraid of using AI for work: 00:15:56How Will uses LLMs to sharpen his thinking: 00:31:01Walleye's approach to using AI to reduce risk: 00:35:32What history can teach us about leading through change: 00:39:10Will's first principles to making better decisions: 00:56:45Why Will journals everyday—and how AI makes it easier: 00:58:58 Links to resources mentioned in the episode:Will England: https://walleyecapital.com/bio/will-england Walleye Capital: https://walleyecapital.com/ Work with Every's consulting team: https://every.to/consulting  Everything we've learned from consulting with clients like Walleye: "How We Built a 7-figure AI Consulting Business in Less Than a Year"

Repasamos el cierre de las bolsas europeas con Carlos Ladero, analista de mercado, mirando hacia compañías como Endesa, BBVA y su OPA a Sabadell, Fluidra, Inditex, Cellnex, Millenium, OHLA y Atrys.

Repasamos el cierre de las bolsas europeas con Carlos Ladero, analista de mercado, mirando hacia compañías como Endesa, BBVA y su OPA a Sabadell, Fluidra, Inditex, Cellnex, Millenium, OHLA y Atrys.

In episode 212, host Galit Friedlander welcomes beloved ballet educator and coach Lisa Ebeyer (Jackson Ballet, Snow White, and LA's go-to ballet whisperer for commercial dancers) for a no-holds-barred convo on dancing through every season of life—without apology. Join Galit and Lisa as they talk about ditching perfectionism, keeping your body strong without surgery, and why “every age is a transitional time.” From her early pro career at 16 to falling back in love with dance at 48, Lisa shares what it means to keep showing up, stretch your big toe (yes, really), and coach with zero BS. This episode is equal parts wisdom, grit, and the kind of honesty dancers don't hear enough of. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/courses/fit-from-home You can connect with Lisa Ebeyer on Instagram: @lisaebeyer Listen to DanceSpeak on Apple Podcasts and Spotify.

Transformative Truth:  Satan cannot stop the advancement and triumph of God's kingdom! Satan Restrained! Revelation 20:1-3 Saints Reign! Revelation 20:4-6 Satan cannot stop the advancement and triumph of God's kingdom. All authority in heaven and on earth has been given to me. Go therefore and make disciples of all nations, baptizing them in the name of the Father and of the Son and of the Holy Spirit, teaching them to observe all that I have commanded you. And behold, I am with you always, to the end of the age. - Matthew 28:18-20

In der neune Serie „Government Cheese“ versucht der ehemalige Gauner Hampton Chambers eine ehrliches Leben zu führen. Auf Disney+ startet die dritte Staffel der Crime-Serie „Will Trent“. Und auf Netflix gibt es eine Doku über einen Raub, wie es ihn eigentlich nur in Hollywoodfilmen hätte geben sollen. Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/was-laeuft-heute >> Artikel zum Nachlesen: https://detektor.fm/kultur/was-laeuft-heute-government-cheese-will-trent-der-millennium-raub

In der neune Serie „Government Cheese“ versucht der ehemalige Gauner Hampton Chambers eine ehrliches Leben zu führen. Auf Disney+ startet die dritte Staffel der Crime-Serie „Will Trent“. Und auf Netflix gibt es eine Doku über einen Raub, wie es ihn eigentlich nur in Hollywoodfilmen hätte geben sollen. Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/was-laeuft-heute >> Artikel zum Nachlesen: https://detektor.fm/kultur/was-laeuft-heute-government-cheese-will-trent-der-millennium-raub

Az előfizetők (de csak a Belső kör és Közösség csomagok tulajdonosai!) már szombat hajnalban hozzájutnak legfrissebb epizódunk teljes verziójához. A hétfőn publikált, ingyen meghallgatható verzió tíz perccel rövidebb. Itt írtunk arról, hogy tudod meghallgatni a teljes adást. 01:40 Autószerelő art of the deal. A bennfentes kereskedő sámán. 06:07 Hiába rántja visszák a kormányt. 09:00 Ha Trump dönti be a NER-t. Frank Drebin a Fehér Házban. 13:18 Nagy roppanás már nem kell. A gazdaság összeroppanás és a politikai változás között nem fennálló korreláció. Legyen már katonai diktatúra! 17:50 A szingapúri miniszterelnök magyarázata. Magyarország ugatva kommunikál.20:57 Title race! A felcsút bajnoki ünneplése. A bilbaói uszályos ünneplés. 25:10 Honosítások szabadfogású birkózásban. Mahacskalai húspiac a világ körül. Küzdősport és szervezett bűnözés. 31:00 A legnagyobb fasz Magyarországon. A komáromi Millenium üzletház és a Vitruvius-tanulmány. 33:58 Lenke néni és a Váci úti Mohu. A magyar üvegvisszaváltás visszafejlődése. Az ember, aki az egészet bojkottálja. 42:19 A giccsfestőnő a Qubit és Szily László cikkeiben, Hankó Balázs, a tökéletes droid. A giccs fokozatai a fideszes kultúrában. 45:49 Tátrai Tátó a 88-as Csoportból. A gruftik visszatérnek. Kubai nők a Körtéren. See omnystudio.com/listener for privacy information.

In episode 211 host Galit Friedlander and guest, powerhouse performer and educator Rob Bynes (Beyoncé's Renaissance Tour, Super Bowl LV, Bad Bunny and more), dive into what really fuels longevity in the dance industry. From getting scouted before he even had a headshot to performing on some of the biggest stages in the world, Rob shares the mindset shifts, self-talk tools, and career pivots that have kept him grounded and growing. We get into training like an athlete, managing pressure under global spotlights, and how Rob's faith plays into his career decisions. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/collections You can connect with Rob Bynes on Instagram. Listen to DanceSpeak on Apple Podcasts and Spotify.

The ladies talk Omarion outbursts, unc dating 101, effective flirt tips, and more! Thanks for listening, we love you Coochadors! Rate, review, and share pretty please :)CoochieQs@gmail.com | @codenamecoochie

April 10-17, 1999 This week Ken wades through a dog related false alarm emergency as he welcomes returning guest Erin Judge and first time guest Jenny Chalikian who have a brand new live record out called "Romantic Comedy: Live! at the Ripped Boddice" Ken, Erin and Jenny discuss Star Trek, Discovery, Xena, the greatness of Jeri Ryan, Star Trek Voyager, hating a Doug Henning future, being gay, gay icons, Hercules, watching TV with your very conservative family, shows shot in New Zealand, Hong Kong action, representation on TV, Dawson's Creek, growing up in Texas, Ken's history with Richard Roundtree, the is Xena butch or not debate, how Jeri Ryan's ex-husband's bad behavior gave us Obama, femme'd out TV stars, Evil Dead The Series, Cynthia Rothrock's greatness, kids who's sketch show was All That, SNL, SNICK, the power of 90s Comedy Central, Are You Being Served?, Alias, why Jennifer Garner always deserves better, Tom Green, Futurama, Family Guy, the post-Simpsons prime time animated world, how Heaven is America, Millenium, X-Files, Walker Texas Ranger, Chuck Norris' syndicated editorial newspaper column, The Awful Truth, Ally McBeal, how television teaches women you either have powerful careers OR a love life but not both, Highlander: The Series, Becker, whatever the hell JAG was, Buffy The Vampire Slayer, loving monsters and loving weeks but not always monsters of the week, how insane people generally are, Laura Kightlinger, Pulp Comics, Kathy Griffith, The Nanny, the Massachusetts factual inacuracies of Dawson's Creek, the double standard of teacher/student relationships dynamics, Delacatessan, Norm, Dr. Quinn, the bizarre-ness of the streaming business model, Irish Wish, Strangers with Candy, Spin City, Just Shoot Me, The Drew Carey Show, nostalgia for Scared Straight, Sabrina the Teenager Witch, Ben Savage working out his family issues via Boy Meets World, Two Guys, a Girl and a Pini's Pizza Place and wishing you could google who somebody is right in front of you because they are clearly famous but you have no idea who they are. 

Listen and learn somethin!  This week on FRN Roundup, Sheila Zilinsky is new on FRN, Ern Baxter Cosmological Christianity, and Philo Sophia returns as the Happy Fools Podcast!   mooEmail: fringeradionetwork@gmail.comWEB: http://www.fringeradionetwork.comX: @FringeRadioNetX: @FRN_Daniel_X

In episode 210, host Galit Friedlander sits down with Miller Daurey, a breakout dance star who left the industry at 19 and made his return three decades later. Join Galit and Miller as they get real about what it's like to step away from dance, the fears that kept him from coming back, and what's changed after 30 years. They dive into how class culture has evolved, the highs and lows of re-entering the scene, and why getting "back to great" isn't always a straight path. Plus, they break down hot topics like filming culture in studios, where AI can for awry, and why dancers love to call themselves rusty after missing class for two minutes (I do it too!). Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/courses/fit-from-home You can connect with Miller Daurey on Instagram: https://www.instagram.com/backtogreat. Listen to Miller's Hey Dancer Podcast: Apple: https://podcasts.apple.com/us/podcast/hey-dancer/id1784126648 Spotify: https://open.spotify.com/show/2jHsC6gn7MylDprwzmjc13?si=Z9F_EH7rQF-G18nlVPjSzg YouTube: https://www.youtube.com/playlist?list=PLwFxLwtPydHKVZMsgnIp9Mn9W6tTj-MST Listen to DanceSpeak on Apple Podcasts and Spotify.

Show NotesWe welcome a new guest Jim Paul, a Christian thinker from the UK L'Abri community. He introduces us to a view of Heaven which is in contrast to the familiar ethereal heaven in our culture.  The familiar view is centuries old with its fluffy clouds and plump babies with wings, but it is a corruption of the Bible's view, which is more earthy and on reflection more attractive.  Jim has written a book on this, “What on Earth is Heaven?”, which we discuss at length. Links:Jim's book “What on Earth is Heaven?”:https://www.amazon.com/What-Earth-Heaven-James-Paul/dp/1789742218 Doubts Aloud Links:Please give feedback and ask questions using:  doubtsaloud@gmail.com

In this episode of Stairway to Eleven, George, John, and TR take a deep dive into the rock music landscape of 2001.  They explore the albums and artists that shaped the sound of the new millennium. Were these records the future of rock or the last echoes of a fading era? Tune in and find out!

In this episode of Stairway to Eleven, George, John, and TR take a deep dive into the rock music landscape of 2001.  They explore the albums and artists that shaped the sound of the new millennium. Were these records the future of rock or the last echoes of a fading era? Tune in and find out!

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Subterranea Outtakes rinde tributo a los hijos de menor edad de los dioses del olimpo guitarrístico del Rock Progresivo, en un programa absolutamente imperdible. David Pintos nos hablará de los trabajos de 2024 de Believe, Anubis, Blind Ego, Millenium y Huis. No te lo pierdas. Edición: David Pintos www.subterranea.eu www.davidpintos.com Escucha este episodio completo y accede a todo el contenido exclusivo de Subterranea Podcast. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/17710

Hola Cabañers: Volvemos con Fincher, esta vez con la interpretación de la novela homónima Millenium, los hombre que no amaban a las mujeres escrita por Stieg Larsson. Ya nos conocéis en La Cabaña, Fincher es de nuestros realizadores favoritos y una vez mas no nos defrauda y disfrutamos con la película, y comentándola claro.. Estructura de programa: 00:00:00 Presentaciones 00:06:20 Milenium, The Girl with the dragon tattoo 01:23:00 Recomendaciones 01:37:20 Comentarios de los Oyentes Starling, Pepu y Solo son los aliados de Lisbeth para llegar a descubrir al asesino. Que lo disfrutéis, Orgullo Cabañer.

How did you know when the '90s were over? (Apart from the date on the calendar!) Was it 9/11? The cancellation of "Beverly Hills, 90210"? When the cell phone started to eat your brain? Audra and Raymond close out Season 2 with this examination of era-ending events and trends. Thank you to the dear Retrophilia listeners for helping the research efforts. This is our 27th episode and we've had a great time wading in and out of the sea of nostalgia.  We will be back with...something! In the meantime, please join Retrophilia on Instagram and Facebook, and continue to share your memories too.

Send me a text! I'd love to know what you're thinking!AI, social media, and other technologies are transforming community, worship, and leadership. To stay effective, ministry leaders must understand these shifts—but also learn from the past. How do today's technologies compare to those of previous eras? This perspective can help us navigate the future.In this episode, I'm joined by Rex Miller, author of The Millennium Matrix. A futurist and expert in leading through change, Rex will share insights on how cultural and technological shifts impact ministry and how we can adapt.THIS EPISODE'S HIGHLIGHTS INCLUDE:Rex Miller explores the impact of communication changes on Christianity over the centuries.The Millennium Matrix analyzes shifts in communication and their effects on church culture.Rex Miller describes the transformation from an oral culture to print culture through technological advancements like the Gutenberg printing press.The broadcast era introduced personality-driven leadership and large-scale praise and worship experiences in churches.Rex Miller explains the transition from analog to digital technology and its wider implications.Digital culture fosters interactive, networked communication that reshapes organizational and cultural dynamics.In the social mobile era, personalized and real-time interactions dominate communication patterns.Rex Miller predicts that AI will enhance personalization and autonomy in community formation.The shift from community-centric oral culture to individualistic broadcast culture reflects changes in authority structures.Markus Watson delves into how shifting cultural frameworks affect pastoral leadership and church practices.Rex Miller sees potential in decentralized, grassroots approaches to modern church gatherings.The opportunities for direct community involvement and personalized content create new forms of ministry.Rex Miller highlights how technological changes continuously reshape leadership and organizational strategies.Church leaders must transition from a certainty mindset to one of curiosity to adapt effectively to cultural changes.RELEVANT RESOURCES AND LINKS:Rex Miller:Rexmiller.comLinked InMind ShiftGenius SparkBooks mentioned:The Millenium Matrix, by Rex MillerNeuromancer, by William GibsonMovies mentioned:Jesus RevolutionPleasantvilleRelated episodes:118. Forecasting and Innovation, with Tom Sine and Dwight Friesen147. Is Innovation Inherently Good? with Andrew Root155: Leadership and Looking to the Future, with Tom SineClick HERE to get my FREE online course, BECOMING LEADERS OF SHALOM.

Cyanotic Cyanotic was first introduced to rave and hardcore in 1995, but was already addicted to the unique sounds of electronic music at the age of 5, influenced by Jean-Michel Jarre's Oxygène album. Since 2015 he has been a member of Death Noize Clan Hungary and since 2024 he has been a member of Hard Session Events, a group based in Austria. His sets are dominated by Early and Millenium sounds - but he also likes to play dark and industrial sounds. Social media: https://www.facebook.com/profile.php?id=100071372976231 Tracklist: 1. Iridium - We Are Alive 2. Ophidian - Silver '22 (The Name Of The Wolf) 3. DJIPE - No More Voices (HVRDTONIC Kick edit) 4. RVOLT - Out Of Control 5. The 3Eyed - Demons In Us 6. The Outside Agency & Ophidian - Return Of The Silence 7. eDUB Ft. Igneon System - Shotgun 8. Ophidian - Dead Air 9. Vein - Ultimate Seduction 10. Vein & The Satan - Synthetic Delight 11. The Outside Agency & Ophidian - Church Of The Silence 12. The Satan - Get The Fuck Up (Original mix) 13. Ophidian - Silver (Extended mix) 14. Ophidian - Lynched (Tymon remix) 15. Forbidden Society & Deathmachine - Rude 16. The Satan - Nothing 17. DJIPE & The Purge - Reset 18. RVOLT & Igneon System - Fucking Noise 19. Ophidian - Angel (Millennium DJ edit) 20. Igneon System & Karbyde - Triggerfinger 21. Industrial Twins - Suppression 22. Shinra Tensei - Move 23. Ophidian & Minkz - The Void (Fade)

This week on the Roach Koach Podcast we answer the question of whether Flymore is Korn or korn or corn as we listen to their 2009 album, Millennium IV V. Topics discussed:-Nicknames-The Korn rating scale-Jonathan Devis-“Life is too long until you die”-Amazon reviews-Filling “a” void-Nothing personal!-Attention to detail in music videos-Songs for the common man-And Canon Talk, where Matt and Lorin decide if Flymore deserve a place in the Nu-Metal Canon. Take a listen!Exclusive episodes and more on the Roach Koach Patreon. New episodes of the Pact every month. Subscribe today! Rate and review Roach Koach on iTunes! We'd appreciate it! Questions about the show? Have album recommendations? Just want to say hi? We'd love to hear from you! Contact the show @RoachKoach on Twitter, Roach Koach on Facebook , Roach Koach on Instagram, or send an email to RoachKoachPodcast at Gmail. Follow the show on Youtube and TikTok! Find every episode of Roach Koach and order your Roach Koach T-shirt at Roach Koach dot com.

Steve and Dave provide an overview of the new army rule for the High Elves of the 41st Millenium, as well as the 8 new detachments and the major unit changes (there's a lot of them) in this new codex from Games Workshop for Warhammer 40,000.

Josh Peck welcomes Dustin Blystone back to discuss his book Metacosm.  To get the audio-only podcast version of full videos and Josh Peck's blog, which includes original articles, show notes, and more, subscribe to Josh's Substack at http://joshpeck.substack.comDonate: http://PayPal.me/JoshPeckDisclosureCashApp: $JoshScottPeck

In episode 209, host Galit Friedlander sits down with Nika Kljun (credits include Beyoncé, Jennifer Lopez, Justin Bieber, Pitbull, Ne-Yo, Jason DeRulo, Paula Abdul, Donna Summer, FIFA World Cup and more) to discuss her journey from a young dancer in Slovenia to performing on the world's biggest stages—and her evolution into teaching and coaching on the convention circuit and beyond. Join Galit and Nika as they explore what makes an extraordinary dancer and the mindset that can either elevate or sabotage you in class. They share insights from Nika's global experiences—from dancing in Paris and London to making it big in Los Angeles—and discuss the realities of choreographing for major artists, along with her secrets for keeping her creativity flowing. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/courses/fit-from-home You can connect with Nika Kljun on Instagram: https://www.instagram.com/nikakljun/?hl=en. Listen to DanceSpeak on Apple Podcasts and Spotify. Follow us on instagram @DanceSpeakPodcast.

Welcome to the Savage Horror Creeps Podcast! We are guides through the world of horror films past, present, and future! Narrating years, decades, sub-genres, subjects, and themes with honest reviews and rankings, no film (or listener) will be spared!   The Savage Horror Creeps are back from their holiday break with the Horror of the Millenium! In it, they go full American Psycho on the best and the worst of 2000! Also, because Cory and Nate end up in a fight - the Creeps NEED THE LISTENERS HELP! Settle the debate --> What are the better films? Hollow Man vs. Leprechaun in Da Hood Pitch Black vs. Hellraiser 5: Inferno   Episode 48: Savage Top Ten American Psycho Ginger Snaps Battle Royale Shadow of the Vampire Final Destination Scream 3 The Convent The Toxic Avenger IV The Cell The GIft   with Honorable Mentions, Horror Awards and nominees, and MORE!   Be sure to subscribe to the Savage Horror Creeps Podcast on: Apple Spotify Or wherever you listen And dont forget to rate/review the podcast! It really helps out the show!      You can email our show at savagehorrorcreeps@gmail.com and interact with us on: Instagram: @savagehorrorcreeps Facebook: The Savage Horror Creeps Podcast Page     Stay tuned for our next episode, Episode 49: The Return of the Living Dead Franchise!

Time Artist Title Duration Album Year 0:00:00 ProgPhonic 171 Intro 0:39 0:00:35 Pattern-Seeking Animals Down The Darkest Road 4:32 Friends of All Creatures 2025 0:08:42 Rohane The Spark 5:44 The Spark 2024 0:14:26 Untold Stories Wind and Memories 10:13 Wind and Memories 2025 0:17:47 Millenium The Sleep Of Reason Produces Monsters 6:11 Hope Dies Last […]

This week, the Under the Hive of Madness crew takes a deeper look into two of the modern Imperium's foundational personalities. Exploring how Euphrati Keeler became the First Saint of the Imperial Creed, and Kyril Sindermann shaped the Inquisition of the 42nd Millenium. Under the Hive of Madness is a Warhammer 40k Podcast diving into the Horror and Grimdark elements of the setting, so expect some adult themes, adult language, and more than a handful of Khorney Jokes! "Bloody paws and bloody claws, only ever revealed after the bloody thaws..." Email the show! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠UndertheHiveofMadness@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Catch-up with Ickbard: ⁠⁠⁠⁠https://linktr.ee/ickbard⁠⁠⁠⁠ Join us today on Discord! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GymDark Gaming⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Become a Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/UndertheHiveofMadness.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Find Us Around the Web:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://linktr.ee/underthehive⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or our Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Underthehiveofmadness.com

In episode 208, host Galit Friedlander sits down with choreographer and educator Phil Wright (Disney's Fam Jam, Lil Nas X, Cardi B) to discuss leaning into your authenticity, navigating the challenges of working with young performers, and harnessing a relentless hustle to build your brand. Join Galit and Phil as they dive into real talk about overcoming insecurities, the power of cold-calling studios, and balancing confidence with vulnerability in the commercial dance world. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/courses/fit-from-home You can connect with Phil Wright on Instagram and request him to teach at your studio here. Register for Chicken Nugget University here. Listen to DanceSpeak on Apple Podcasts and Spotify.

Scripture describes a time in the future when the Messiah will be the ruler of the earth for 1000 years. We call it the Millennium! What will the earth be like when a perfect ruler who loves every inhabitant the same is in charge? Let's imagine it together. Jesus as king of the earth!!

STERNENGESCHICHTEN LIVE TOUR 2025! Tickets unter https://sternengeschichten.live Die "Millenium-Simulation" hat die Entwicklung des Kosmos simuliert. Aber wie simuliert man das gesamte Universum und warum will man das überhaupt machen? Das erfahrt ihr in der neuen Folge der Sternengeschichten. Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

Intro  05:30 Simon Kimberg Trilogy, Rey movie, and the best of Disney plus  22:50 Thrawn movie and best books  38:50 Skeleton Crew  47:45 Favorite things about Star Wars, Darth Vader  1:02:30 Least favorite things about Star Wars  1:23:45 Would you rather? 9-5 job on the Millenium falcon with Han and Chewie or be in a X wing battle once a month for the rest of life… if you were the top Jedi master, would you allow your subjects attachments with the risk of corruption?  1:31:15 Favorite lightsaber color & would you rather be stuck in the dune sea or in Hoth  1:41:35 strongest on screen Jedi vs strongest on screen sith… what if Luke and Leah switched spots as babies? & what if Rey took Kylo's hand to join the dark side  1:56:40 What if Grogu stayed with Luke… would you use the dark side to save a loved one?  Follow us on social media: Twitter/Instagram/TikTok: @whysosidiouspod YouTube: www.youtube.com/@whysosidiouspod?app=desktop Email us questions/requests: whysosidious@yahoo.com Subscribe, Rate, and Review! Send us your questions/comments!Support the show

Are you ready for Christmas? Are you looking for HOPE? Will you open the gift of HOPE this Holiday Season? Christmas means more hope. Today on Like It Matters Radio Mr. Black wants to give you the gift of HOPE. What is the meaning of Christmas? That question has been asked for Millenium, and today Mr. Black will attempt to bring his listeners to an understanding and the opportunity to open the gift that is freely given by the Child in the manger who was wrapped in swaddling clothes. Listeners will learn more about the history of Christmas, the polemic nature of the Bible and the battle for the truth, that brings understanding, that brings hope! This is the story of Christmas. Tune into this hour of power as Mr. Black brings additional gifts of Inspiration, Education and Application. Helping listeners remember: When you live your life like it matters- it does! Merry Christmas! Be sure to Like and Follow us on our facebook page!www.facebook.com/limradio Instagram @likeitmattersradioTwitter @likeitmatters Get daily inspiration from our blog www.wayofwarrior.blog Learn about our non profit work at www.givelikeitmatters.com Check out our training website www.LikeItMatters.Net Always available online at www.likeitmattersradio.comSee omnystudio.com/listener for privacy information.

In episode 207, host Galit Friedlander sits down with Olga Sokolova (international dancer, movement specialist, and creative who's worked with Pharrell, Cartier, and Google Watch) to discuss the intersection of dance, healing, and personal expression. Join Galit and Olga as they dive into traditions of various Eastern training methods, the impact of commercial dance expectations, and the journey to rediscovering divine femininity. From unlocking the body's natural healing potential to the art of flexibility and strength, this episode offers deep insights into owning your creative path and embracing movement as a form of self-discovery. Follow Galit: Instagram - https://www.instagram.com/gogalit Website - https://www.gogalit.com/ Fit From Home - https://galit-s-school-0397.thinkific.com/courses/fit-from-home You can connect with Olga on Instagram and book a session through this website. Listen to DanceSpeak on Apple Podcasts and Spotify.